The following abstracts represent the oral presentations given at IWWM-12 (Prague-2024), Session 11: Chemoimmunotherapy in WM II
Session Chairs: Veronique Leblond, Meletios Dimopoulos
Role of Proteasome Inhibitors in WM Kersten (The Netherlands)
Management of Transformed WM Durot (France)
Final Analysis of Innovative Study; Ibrutinib Rituximab vs. Placebo/Rituximab: Clinical and Genomic Findings Buske (Germany)
Comparative Outcomes of Benda-R vs. Ibrutinib in Frontline WM Abeykoon (USA)
Prague 2024 Conference Chairs
The Prague 2024 Scientific Committee members:
Ranjana Advani, MD (USA)
Xinxin Cao, MD (China)
Jorge Castillo, MD (USA)
Ramon Garcia Sanz, MD PhD (Spain)
Moshe Gatt, MD HMO (Israel)
Prashant Kapoor, MD (USA)
Efstathios Kastritis, MD (Greece)
M.J. Kersten, MD PhD AMC (NL)
Merav Leiba, MD (Israel)
Lugui Qiu, MD (China)
Naohiro Sekiguchi, MD, PhD (Japan)
Constantine Tam, MD, FRACP, FRCPA (Aus)
Alessandra Tedeschi, MD (Italy)
Judith Trotman, MD, FRACP, FRCPA (Aus)
Marzia Varettoni, MD (Italy)
Choose from the following list of Prague 2024 (IWWM-12) conference sessions:
Session 4: Single Cell RNA Analysis
Session 6: Molecular Diagnostics in WM
Session 9: Tumor Immune Microenvironment
Session 10: Chemoimmunotherapy in WM I
Session 11: Chemoimmunotherapy in WM II
Session 12: BTK-Inhibitors in WM I
Session 13: BTK-Inhibitors in WM II
Session 15: BTK-I Intolerant and Resistant Disease
Session 18: Special Topics Lectures
Session 19: Plenary Session II
Session 21: Novel Drug Development for WM
Session 22: Clinical Trials in Progress for WM I
Consensus Panel Reports from the 12th International Workshop on Waldenstrom's Macroglobulinemia
Consensus Panel 3 on the Management of Patients with High-Risk Disease
Consensus Panel 4 on the Management of Patients with non-IgM Lymphoplasmacytic Lymphoma
Consensus Panel 6 on Diagnosis and Management of Transformed Waldenstrom's Macroglobulinemia
Copyright © 2026 International Waldenström's Macroglobulinemia Workshops. All Rights Reserved.